Tumour-immune cell interactions modulated by chemokines

Bibliography

• Imaizumi A, Torisu M, Yoshida T. A chemotactic factor for rat thymocytes may regulate T-lymphocyte migration toward the thymic microenvironment. Cell Immunol 1987;108(1):53-63
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-7
   PubMed Web of Science ®Google Scholar
• Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392(6676):565-8
   PubMed Web of Science ®Google Scholar
• Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4(7):540-50
   PubMed Web of Science ®Google Scholar
• Rossi D, Zlotnik A. The biology of chemokines and their receptors. Ann Rev Immunol 2000;18217-42
   Google Scholar
• Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005;280(42):35760-6
   PubMed Web of Science ®Google Scholar
• Petkovic V, Moghini C, Paoletti S, et al. I-TAC/CXCL11 is a natural antagonist for CCR5. J Leukoc Biol 2004;76(3):701-8
   PubMed Web of Science ®Google Scholar
• Petkovic V, Moghini C, Paoletti S, et al. Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. A human chemokine with a regulatory role. J Biol Chem 2004;279(22):23357-63
   PubMed Web of Science ®Google Scholar
• Loetscher P, Pellegrino A, Gong JH, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001;276(5):2986-91
   PubMed Web of Science ®Google Scholar
• Hadley TJ, Peiper SC. From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Blood 1997;89(9):3077-91
   PubMed Web of Science ®Google Scholar
• Nibbs RJ, Wylie SM, Yang J, et al. Cloning and characterization of a novel promiscuous human β-chemokine receptor D6. J Biol Chem 1997;272(51):32078-83
   PubMed Web of Science ®Google Scholar
• Ali H, Richardson RM, Haribabu B, Snyderman R. Chemoattractant receptor cross-desensitization. J Biol Chem 1999;274(10):6027-30
   PubMed Web of Science ®Google Scholar
• Kurt RA, Baher A, Wisner KP, et al. Chemokine receptor desensitization in tumor-bearing mice. Cell Immunol 2001;207(2):81-8
   PubMed Web of Science ®Google Scholar
• Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381(6584):667-73
   PubMed Web of Science ®Google Scholar
• Gershengorn MC, Geras-Raaka E, Varma A, Clark-Lewis I. Chemokines activate Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture. J Clin Invest 1998;102(8):1469-72
   PubMed Web of Science ®Google Scholar
• Rot A, Von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Ann Rev Immunol 2004;22891-928
   Google Scholar
• Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 2006;7(12):243
   PubMed Web of Science ®Google Scholar
• Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998;393(6685):591-4
   PubMed Web of Science ®Google Scholar
• Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000;289(5480):739-45
   PubMed Web of Science ®Google Scholar
• Thelen M. Dancing to the tune of chemokines. Nat Immunol 2001;2(2):129-34
   PubMed Web of Science ®Google Scholar
• Rodriguez-Frade JM, Mellado M, Martinez A. Chemokine receptor dimerization: two are better than one. Trends Immunol 2001;22(11):612-7
   PubMed Web of Science ®Google Scholar
• Vlahakis SR, Villasis-Keever A, Gomez T, et al. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J Immunol 2002;169(10):5546-54
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Adams DH, Hubscher S, et al. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β. Nature 1993;361(6407):79-82
   PubMed Web of Science ®Google Scholar
• Rot A. Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. Immunol Today 1992;13(8):291-4
   PubMedGoogle Scholar
• Appay V, Rowland-Jones SL. Rantes: a versatile and controversial chemokine. Trends Immunol 2001;22(2):83-7
   PubMed Web of Science ®Google Scholar
• Johnson Z, Proudfoot AE, Handel TM. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev 2005;16(6):625-36
   PubMed Web of Science ®Google Scholar
• Potzinger H, Geretti E, Brandner B, et al. Developing chemokine mutants with improved proteoglycan affinity and knocked-out GPCR activity as anti-inflammatory recombinant drugs. Biochem Soc Trans 2006;34(Pt 3):435-7
   PubMed Web of Science ®Google Scholar
• Kohrgruber N, Groger M, Meraner P, et al. Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J Immunol 2004;173(11):6592-602
   PubMed Web of Science ®Google Scholar
• Poznansky MC, Olszak IT, Foxall R, et al. Active movement of T cells away from a chemokine. Nat Med 2000;6(5):543-8
   PubMed Web of Science ®Google Scholar
• Ogilvie P, Paoletti S, Clark-Lewis I, Uguccioni M. Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood 2003;102(3):789-94
   PubMed Web of Science ®Google Scholar
• Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410(6824):50-6
   PubMed Web of Science ®Google Scholar
• Schutyser E, Su Y, Yu Y, et al. Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur Cytokine Netw 2007;18(2):59-70
   PubMed Web of Science ®Google Scholar
• Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96(8):2655-63
   PubMed Web of Science ®Google Scholar
• Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003;89(3):462-73
   PubMed Web of Science ®Google Scholar
• Bian XW, Yang SX, Chen JH, et al. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery 2007;61(3):570-8
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1α in multiple myeloma. Mol Cancer Ther 2002;1(7):539-44
   PubMed Web of Science ®Google Scholar
• Johrer K, Janke K, Krugmann J, et al. Transendothelial migration of myeloma cells is increased by TNF-a via TNF-R2 and autocrine upregulation of MCP-1. Clin Cancer Res 2004;10(6):1901-10
   PubMed Web of Science ®Google Scholar
• Craig MJ, Loberg RD. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Rev 2006;25(4):611-9
   PubMed Web of Science ®Google Scholar
• Kleinhans M, Tun-Kyi A, Gilliet M, et al. Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. Blood 2003;101(4):1487-93
   PubMed Web of Science ®Google Scholar
• Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003;9(10 Pt 1):3625-34
   PubMed Web of Science ®Google Scholar
• Seidl H, Richtig E, Tilz H, et al. Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol 2007;38(5):768-80
   PubMed Web of Science ®Google Scholar
• Zlotnik A. Chemokines and cancer. Int J Cancer 2006;119(9):2026-9
   PubMed Web of Science ®Google Scholar
• Singh S, Sadanandam A, Singh RK. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 2007;26(3-4):453-67
   PubMed Web of Science ®Google Scholar
• Strieter RM, Burdick MD, Mestas J, et al. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006;42(6):768-78
   PubMed Web of Science ®Google Scholar
• Zhu YM, Woll PJ. Mitogenic effects of interleukin-8/CXCL8 on cancer cells. Future Oncol 2005;1(5):699-704
   PubMedGoogle Scholar
• Johrer K, Zelle-Rieser C, Perathoner A, et al. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin Cancer Res 2005;11(7):2459-65
   PubMed Web of Science ®Google Scholar
• Kleeff J, Kusama T, Rossi DL, et al. Detection and localization of Mip-3α/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer 1999;81(4):650-7
   PubMed Web of Science ®Google Scholar
• Giuliani N, Bonomini S, Romagnani P, et al. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 2006;91(11):1489-97
   PubMed Web of Science ®Google Scholar
• Addison CL, Arenberg DA, Morris SB, et al. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 2000;11(2):247-61
   PubMed Web of Science ®Google Scholar
• Zipin-Roitman A, Meshel T, Sagi-Assif O, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007;67(7):3396-405
   PubMed Web of Science ®Google Scholar
• Robledo MM, Bartolome RA, Longo N, et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001;276(48):45098-105
   PubMed Web of Science ®Google Scholar
• Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005;23(7):879-94
   PubMed Web of Science ®Google Scholar
• Wysoczynski M, Reca R, Ratajczak J, et al. Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. Blood 2005;105(1):40-8
   PubMed Web of Science ®Google Scholar
• Mocellin S, Nitti D. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. Med Res Rev 2007;In Press
   PubMedGoogle Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203-13
   PubMed Web of Science ®Google Scholar
• Hojo S, Koizumi K, Tsuneyama K, et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007;67(10):4725-31
   PubMed Web of Science ®Google Scholar
• Kondo T, Ito F, Nakazawa H, et al. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 2004;171(6 Pt 1):2171-5
   PubMed Web of Science ®Google Scholar
• Kondo T, Nakazawa H, Ito F, et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006;97(8):780-6
   PubMed Web of Science ®Google Scholar
• Monti P, Leone BE, Marchesi F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 2003;63(21):7451-61
   PubMed Web of Science ®Google Scholar
• Moran CJ, Arenberg DA, Huang CC, et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 2002;8(12):3803-12
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3(11):991-8
   PubMed Web of Science ®Google Scholar
• Marrogi AJ, Munshi A, Merogi AJ, et al. Study of tumor infiltrating lymphocytes and transforming growth factor-β as prognostic factors in breast carcinoma. Int J Cancer 1997;74(5):492-501
   PubMed Web of Science ®Google Scholar
• Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58(16):3491-4
   PubMed Web of Science ®Google Scholar
• Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61(10):3932-6
   PubMed Web of Science ®Google Scholar
• Tinhofer I, Rubenzer G, Holler C, et al. Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 2006;108(9):2950-6
   PubMed Web of Science ®Google Scholar
• Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25(3):315-22
   PubMed Web of Science ®Google Scholar
• Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002;13(2):143-54
   PubMed Web of Science ®Google Scholar
• Luboshits G, Shina S, Kaplan O, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999;59(18):4681-7
   PubMed Web of Science ®Google Scholar
• Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-α. Eur J Immunol 2002;32(2):404-12
   PubMed Web of Science ®Google Scholar
• Ghilardi G, Biondi ML, La TA, Battaglioli L, Scorza R. Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele. Clin Chem 2005;51(2):452-5
   PubMed Web of Science ®Google Scholar
• Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196(3):254-65
   PubMed Web of Science ®Google Scholar
• Kalinski P, Giermasz A, Nakamura Y, et al. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 2005;42(4):535-9
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Bai F, Painter JS, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007;109(11):4816-24
   PubMed Web of Science ®Google Scholar
• Esendagli G, Bruderek K, Goldmann T, et al. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008;59(1):32-40
   PubMedGoogle Scholar
• Jurisic V, Srdic T, Konjevic G, et al. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med. Oncol. 200724(3):312-317.
   PubMed Web of Science ®Google Scholar
• Bamias A, Tsiatas ML, Kafantari E, et al. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol Oncol 2007;106(1):75-81
   PubMed Web of Science ®Google Scholar
• Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006;12(2):214-9
   PubMed Web of Science ®Google Scholar
• Ullrich E, Bonmort M, Mignot G, et al. Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Res 2007;67(3):851-3
   PubMed Web of Science ®Google Scholar
• Xin H, Kikuchi T, Andarini S, et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005;35(5):1371-80
   PubMed Web of Science ®Google Scholar
• Starnes T, Rasila KK, Robertson MJ, et al. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol 2006;34(8):1101-5
   PubMed Web of Science ®Google Scholar
• Shellenberger TD, Wang M, Gujrati M, et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res 2004;64(22):8262-70
   PubMed Web of Science ®Google Scholar
• Roda JM, Parihar R, Magro C, et al. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res 2006;66(1):517-26
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001;106(3):263-6
   PubMed Web of Science ®Google Scholar
• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449(7161):419-26
   PubMed Web of Science ®Google Scholar
• Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7(12):1339-46
   PubMed Web of Science ®Google Scholar
• Vanbervliet B, Driss-Vermare N, Massacrier C, et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med 2003;198(5):823-30
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Cheng P, Mottram P, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004;64(16):5535-8
   PubMed Web of Science ®Google Scholar
• D'Amico G, Frascaroli G, Bianchi G, et al. Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nat Immunol 2000;1(5):387-91
   PubMed Web of Science ®Google Scholar
• Feijoo E, Alfaro C, Mazzolini G, et al. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 2005;116(2):275-81
   PubMed Web of Science ®Google Scholar
• Frederick MJ, Clayman GL. Chemokines in cancer. Expert Rev Mol Med 2001;3(19):18-31
   Google Scholar
• Shurin GV, Ferris RL, Tourkova IL, et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol 2005;174(9):5490-8
   PubMed Web of Science ®Google Scholar
• Omata N, Yasutomi M, Yamada A, et al. Monocyte chemoattractant protein-1 selectively inhibits the acquisition of CD40 ligand-dependent IL-12-producing capacity of monocyte-derived dendritic cells and modulates Th1 immune response. J Immunol 2002;169(9):4861-6
   PubMed Web of Science ®Google Scholar
• Remmel E, Terracciano L, Noppen C, et al. Modulation of dendritic cell phenotype and mobility by tumor cells in vitro. Hum Immunol 2001;62(1):39-49
   PubMed Web of Science ®Google Scholar
• Dell'Agnola C, Biragyn A. Clinical utilization of chemokines to combat cancer: the double-edged sword. Expert Rev Vaccines 2007;6(2):267-83
   PubMed Web of Science ®Google Scholar
• Shurin MR, Shurin GV, Lokshin A, et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 2006;25(3):333-56
   PubMed Web of Science ®Google Scholar
• Peng L, Shu S, Krauss JC. Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells. Cancer Res 1997;57(21):4849-54
   PubMed Web of Science ®Google Scholar
• Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001;2(2):102-7
   PubMed Web of Science ®Google Scholar
• Karpus WJ, Lukacs NW, Kennedy KJ, et al. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J Immunol 1997;158(9):4129-36
   PubMed Web of Science ®Google Scholar
• Cridge TJ, Horowitz KM, Marinucci MN, et al. Functional and molecular alterations in T Cells induced by CCL5. Immunol Invest 2006;35(1):115-32
   PubMed Web of Science ®Google Scholar
• Adler EP, Lemken CA, Katchen NS, Kurt RA. A dual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett 2003;90(2-3):187-94
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9
   PubMed Web of Science ®Google Scholar
• Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006;97(11):1139-46
   PubMed Web of Science ®Google Scholar
• Romagnani P, Maggi L, Mazzinghi B, et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol 2005;116(6):1372-9
   PubMed Web of Science ®Google Scholar
• Dufour JH, Dziejman M, Liu MT, et al. IFN-γ-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002;168(7): 3195-204
   PubMed Web of Science ®Google Scholar
• Heller EA, Liu E, Tager AM, et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006;113(19):2301-12
   PubMed Web of Science ®Google Scholar
• Luster AD, Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993;178(3):1057-65
   PubMed Web of Science ®Google Scholar
• Liu YQ, Poon RT, Hughes J, et al. Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma. World J Gastroenterol 2005;11(2):164-70
   PubMed Web of Science ®Google Scholar
• Winter D, Moser J, Kriehuber E, et al. Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients. J Immunol 2007;179(6):4272-82
   PubMed Web of Science ®Google Scholar
• Kataoka S, Konishi Y, Nishio Y. Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. DNA Cell Biol 2004;23(9):549-60
   PubMed Web of Science ®Google Scholar
• Hanamoto H, Nakayama T, Miyazato H, et al. Expression of CCL28 by Reed-Sternberg cells defi nes a major subtype of classical Hodgkin's disease with frequent infi ltration of eosinophils and/or plasma cells. Am J Pathol 2004;164 (3):997-1006
   Google Scholar
• Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 2007;178(7):4222-9
   PubMed Web of Science ®Google Scholar
• Kadin M, Butmarc J, Elovic A, Wong D. Eosinophils are the major source of transforming growth factor-β 1 in nodular sclerosing Hodgkin's disease. Am J Pathol 1993;142(1):11-6
   PubMed Web of Science ®Google Scholar
• Liu LY, Bates ME, Jarjour NN, et al. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-α. J Immunol 2007;179(7):4840-8
   PubMed Web of Science ®Google Scholar
• Mule JJ, Custer M, Averbook B, et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 1996;7(13):1545-53
   PubMed Web of Science ®Google Scholar
• Crittenden M, Gough M, Harrington K, et al. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res 2003;63(17):5505-12
   PubMed Web of Science ®Google Scholar
• Braun SE, Chen K, Foster RG, et al. The CC chemokine CKβ-11/MIP-3β/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 2000;164(8):4025-31
   PubMed Web of Science ®Google Scholar
• Vicari AP, It-Yahia S, Chemin K, et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000;165(4):1992-2000
   PubMed Web of Science ®Google Scholar
• Guiducci C, Di CE, Parenza M, et al. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J Immunol 2004;172(7):4026-36
   PubMed Web of Science ®Google Scholar
• Kanagawa N, Niwa M, Hatanaka Y, et al. CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. Int J Cancer 2007;121(9):2013-22
   PubMed Web of Science ®Google Scholar
• Chu Y, Yang X, Xu W, et al. In situ expression of IFN-γ-inducible T cell α chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression. Cancer Immunol Immunother 2007;56(10):1539-49
   PubMed Web of Science ®Google Scholar
• Hisada M, Yoshimoto T, Kamiya S, et al. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Ther 2004;11(4):280-8
   PubMed Web of Science ®Google Scholar
• Gao JQ, Kanagawa N, Motomura Y, et al. Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer. Gene Ther 2007;14(6):491-502
   PubMed Web of Science ®Google Scholar
• Pertl U, Luster AD, Varki NM, et al. IFN-γ-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol 2001;166(11):6944-51
   PubMed Web of Science ®Google Scholar
• Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003;101(5):1718-26
   PubMed Web of Science ®Google Scholar
• Russell HV, Strother D, Mei Z, et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 2007;30(2):227-33
   PubMed Web of Science ®Google Scholar
• Liang CM, Ye SL, Zhong CP, et al. More than chemotaxis: a new anti-tumor DC vaccine modified by rAAV2-SLC. Mol Immunol 2007;44(15):3797-804
   PubMed Web of Science ®Google Scholar
• Westermann J, Nguyen-Hoai T, Baldenhofer G, et al. CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther 2007;14(6):523-32
   PubMed Web of Science ®Google Scholar
• Yang SC, Hillinger S, Riedl K, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004;10(8):2891-901
   PubMed Web of Science ®Google Scholar
• Terando A, Roessler B, Mule JJ. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther 2004;11(3):165-73
   PubMed Web of Science ®Google Scholar
• Biragyn A, Ruffini PA, Coscia M, et al. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 2004;104(7):1961-9
   PubMed Web of Science ®Google Scholar
• Schiavo R, Baatar D, Olkhanud P, et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006;107(12):4597-605
   PubMed Web of Science ®Google Scholar
• Marin V, Kakuda H, Dander E, et al. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-ζ activating signal. Exp Hematol 2007;35(9):1388-97
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72
   PubMed Web of Science ®Google Scholar
• D'Elios MM, Amedei A, Cappon A, et al. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. FEMS Immunol Med Microbiol 2007;50(2):157-64
   PubMed Web of Science ®Google Scholar
• Amedei A, Cappon A, Codolo G, et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 2006;116(4):1092-101
   PubMed Web of Science ®Google Scholar
• Rathinavelu S, Kao JY, Zavros Y, Merchant JL. Helicobacter pylori outer membrane protein 18 (Hp1125) induces dendritic cell maturation and function. Helicobacter 2005;10(5):424-32
   PubMed Web of Science ®Google Scholar
• Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007;133(2):659-72
   PubMed Web of Science ®Google Scholar
• Loberg RD, Ying C, Craig M, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007;67(19):9417-24
   PubMed Web of Science ®Google Scholar
• Reali E, Spisani S, Gavioli R, et al. IL-8 enhances antibody-dependent cellular cytotoxicity in human neutrophils. Immunol Cell Biol 1995;73(3):234-8
   PubMed Web of Science ®Google Scholar
• Dehqanzada ZA, Storrer CE, Hueman MT, et al. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 2006;12(2):478-86
   PubMed Web of Science ®Google Scholar
• Lavergne E, Combadiere C, Iga M, et al. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol 2004;173(6):3755-62
   PubMed Web of Science ®Google Scholar
• Lee JM, Merritt RE, Mahtabifard A, et al. Intratumoral expression of macrophage-derived chemokine induces CD4+ T cell-independent antitumor immunity in mice. J Immunother 2003;26(2):117-29
   PubMed Web of Science ®Google Scholar
• Guo J, Chen T, Wang B, et al. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 2003;89(1):1-7
   PubMed Web of Science ®Google Scholar
• Palmer K, Hitt M, Emtage PC, et al. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther 2001;8(4):282-90
   PubMed Web of Science ®Google Scholar
• Zeng Y, Huebener N, Fest S, et al. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res 2007;67(5):2331-8
   PubMed Web of Science ®Google Scholar
• Yang SC, Hillinger S, Riedl K, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004;10(8):2891-901
   PubMed Web of Science ®Google Scholar
• Redondo-Munoz J, Terol MJ, Garcia-Marco JA, Garcia-Pardo A. MMP-9 is upregulated by CCL21/CCR7 interaction via ERK1/2 signaling and is involved in CCL21-driven B-CLL cell invasion and migration. Blood 2008;111(1):383-6
   PubMed Web of Science ®Google Scholar
• Chunsong H, Yuling H, Li W, et al. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. J Immunol 2006;177(10):6713-22
   PubMed Web of Science ®Google Scholar
• Ticchioni M, Essafi M, Jeandel PY, et al. Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene 2007;26(50):7081-91
   PubMed Web of Science ®Google Scholar
• Burkle A, Niedermeier M, Schmitt-Graff A, et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B cell chronic lymphocytic leukemia. Blood 2007;110(9):3316-25
   PubMed Web of Science ®Google Scholar
• Kawada K, Sonoshita M, Sakashita H, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004;64(11):4010-7
   PubMed Web of Science ®Google Scholar
• Kawada K, Hosogi H, Sonoshita M, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007;26(32):4679-88
   PubMed Web of Science ®Google Scholar
• Juarez J, Baraz R, Gaundar S, et al. Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia. Haematologica 2007;92(4):450-9
   PubMed Web of Science ®Google Scholar
• Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 2004;4(11):901-9
   PubMed Web of Science ®Google Scholar
• Ao M, Franco OE, Park D, et al. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 2007;67(9):4244-53
   PubMed Web of Science ®Google Scholar
• Juarez J, Dela PA, Baraz R, et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 2007;21(6):1249-57
   PubMed Web of Science ®Google Scholar
• Liang Z, Yoon Y, Votaw J, et al. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005;65(3):967-71
   PubMed Web of Science ®Google Scholar
• Lapteva N, Yang AG, Sanders DE, et al. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2005;12(1):84-9
   PubMed Web of Science ®Google Scholar
• Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196(2):304-12
   PubMed Web of Science ®Google Scholar
• Murga JD, Franti M, Pevear DC, et al. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2006;50(10):3289-96
   PubMed Web of Science ®Google Scholar
• Borczuk AC, Papanikolaou N, Toonkel RL, et al. Lung adenocarcinoma invasion in TGFβRII-deficient cells is mediated by CCL5/RANTES. Oncogene 2007;27(4):557-64
   PubMed Web of Science ®Google Scholar
• Loberg RD, Ying C, Craig M, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007;67(19):9417-24
   PubMed Web of Science ®Google Scholar
• Vanderkerken K, Broek IV, Eizirik DL, et al. Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis 2002;19(1):87-90
   PubMed Web of Science ®Google Scholar